CNS Pharmaceuticals – Consensus Indicates Potential 323.7% Upside

Broker Ratings

CNS Pharmaceuticals found using ticker (CNSP) have now 2 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 8 and 7 and has a mean target at 7.5. With the stocks previous close at 1.77 this would imply there is a potential upside of 323.7%. The 50 day moving average now sits at 2.19 and the 200 day MA is 2.01. The company has a market cap of $42m. Find out more information at:

CNS Pharmaceuticals, a biopharmaceutical company, engages in the development of anti-cancer drug candidates for primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. CNS Pharmaceuticals was founded in 2017 and is based in Houston, Texas.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp